Glucotrack, Inc. (GCTK) - Dilution Analysis

10-Q filing | 6.3M shares outstanding

POS AM filing: This prospectus relates to the offer and resale of up to 20,060,000 shares of our common stock by Sixth Borough Capital Fund, LP.

8-K filing: Glucotrack, Inc. exchanged a partitioned promissory note for 895,000 shares of its common stock with an investor. ($0.6M proceeds)

10-K filing | 1.9M shares outstanding

S-3 filing: This prospectus relates to the resale from time-to-time of up to 3,224,803 shares of common stock of Glucotrack, Inc. by the selling stockholders identified in this prospectus.

8-K filing: Glucotrack, Inc. completed a private placement of securities, issuing pre-funded warrants and common warrants to an investor, resulting in gross proceeds of approximately $4.0 million. ($8.0M proceeds)

10-Q filing | 0.9M shares outstanding

S-1 filing: This prospectus relates to the offer and resale of up to 20,060,000 shares of our common stock by Sixth Borough Capital Fund, LP.

10-Q filing | 0.9M shares outstanding

8-K filing: Stock split 1-for-60 | Outstanding: 28,642,809 → 567,456

10-Q filing | 28.6M shares outstanding

10-K filing | 25.6M shares outstanding

8-K filing: Glucotrack, Inc. issued 132,036 shares of common stock to the Note Investor upon conversion of debt, 9,760 shares of common stock to Holders upon conversion of convertible promissory notes, and 2,749,817 shares of common stock to the Note Investor and Holders upon the exchange of Series B Warrants.

8-K filing: Glucotrack, Inc. entered into a securities purchase agreement for the registered direct offering and sale of 2,638,042 shares of common stock at $1.15 per share, with gross proceeds of approximately $3.03 million. ($3.03M proceeds)

8-K filing: Stock split 1-for-20 | Outstanding: 5,594,880 → 7,774,574

8-K filing: Glucotrack, Inc. issued 134,785,015 shares of Common Stock upon the exchange of 6,950,240 Series B Warrants from January 6, 2025 through January 13, 2025, pursuant to an exemption from registration under Section 3(a)(9) of the Securities Act of 1933.

8-K filing: Glucotrack, Inc. closed a public offering of shares, warrants, and pre-funded warrants and a concurrent private placement involving debt conversion, and intends to hold a meeting to approve a reverse stock split at a ratio of between 1-for-2 and 1-for-20.

8-K filing: Glucotrack, Inc. completed a public offering of common stock, pre-funded warrants, and warrants, along with a concurrent private placement converting debt into common stock and warrants. ($7.48M proceeds)

10-Q filing | 5.6M shares outstanding

S-1/A filing: The company entered into multiple private placement agreements to issue common stock, promissory notes and warrants.

S-1/A filing: This S-1/A filing relates to an offering of common stock, pre-funded warrants, Series A common warrants, and Series B common warrants by Glucotrack, Inc.

S-1/A filing: Glucotrack, Inc. is offering shares of common stock together with Series A common warrants and Series B common warrants, as well as pre-funded warrants, and registering shares of common stock issuable upon exercise of the warrants.

S-1/A filing: GlucoTrack, Inc. is offering shares of common stock, pre-funded warrants, Series A common warrants, Series B common warrants, and placement agent warrants, as detailed in the S-1/A filing.

S-3/A filing: The company is filing an S-3/A to register for the potential sale of up to $30,000,000 of common stock, preferred stock, and debt securities.

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, and debt securities for up to $30,000,000.

S-1 filing: S-1 filing for an offering of common stock, pre-funded warrants, and common warrants by Glucotrack, Inc.

8-K filing: Glucotrack, Inc. converted $259,300.00 of debt to common stock at $1.02 per share and issued three warrants to an investor, exercisable for common stock at varying prices. ($0.26M proceeds)

10-Q filing | 5.2M shares outstanding

8-K filing: Glucotrack, Inc. entered into a convertible promissory note agreement for $4,000,000 and three warrant agreements with an investor, subject to stockholder approval for conversion.

8-K filing: Glucotrack, Inc. completed a private placement of unsecured promissory notes and warrants, raising $100,000 and issuing warrants to purchase up to 300,000 shares of common stock. ($0.1M proceeds)

8-K filing: Stock split 1-for-5 | Outstanding: 24,959,768 → 5,478,599

10-Q filing | 25.0M shares outstanding

10-K filing | 26.8M shares outstanding

10-Q filing | 23.0M shares outstanding

10-Q filing | 20.9M shares outstanding

10-Q filing | 20.9M shares outstanding

8-K filing: GlucoTrack, Inc. closed a firm commitment underwritten public offering of common stock, selling 7,352,942 shares at $1.36 per share, with gross proceeds expected to be approximately $10.0 million before deducting underwriting discounts and other estimated expenses. ($10.0M proceeds)

10-K filing | 15.5M shares outstanding

10-Q filing | 15.5M shares outstanding

10-Q filing | 15.5M shares outstanding

10-Q filing | 15.5M shares outstanding

10-K filing | 15.5M shares outstanding

10-Q filing | 15.4M shares outstanding

S-3 filing: Integrity Applications, Inc. may offer and sell up to $100 million in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-Q filing | 15.4M shares outstanding

10-Q filing | 200.8M shares outstanding

10-K filing | 200.8M shares outstanding

10-Q filing | 200.7M shares outstanding

10-Q filing | 200.5M shares outstanding

10-Q filing | 200.5M shares outstanding

10-K filing | 199.4M shares outstanding